Feasibility of Extrapolating Randomly Taken Plasma Samples to Trough Levels for Therapeutic Drug Monitoring Purposes of Small Molecule Kinase Inhibitors by Ruben A. G. van Eerden, Esther Oomen-de Hoop, Aad Noordam, Ron H. J. Mathijssen, Stijn L. W. Koolen

Get full text

Tamoxifen use and potential effects on liver parenchyma: A long‐term prospective transient elastographic evaluation by C. Louwrens Braal, Robert J. deKnegt, Agnes Jager, Stijn L. W. Koolen, Ron H. J. Mathijssen, Karel Eechoute

Get full text

Clinical <i>CYP2D6</i> Genotyping to Personalize Adjuvant Tamoxifen Treatment in ER-Positive Breast Cancer Patients: Current Status of a Controversy by Tessa A. M. Mulder, Mirjam de With, Marzia del Re, Romano Danesi, Ron H. J. Mathijssen, Ron H. N. van Schaik

Get full text

Treatment and Implications of Vascular Endothelial Growth Factor Inhibitor‐Induced Blood Pressure Rise: A Clinical Cohort Study by Daan C. H. van Dorst, Sumeyye Kabadayi, Esther Oomen‐de Hoop, A.H. Jan Danser, Ron H. J. Mathijssen, Jorie Versmissen

Get full text

Clinically relevant drug interactions with multikinase inhibitors: a review by Koen G. A. M. Hussaarts, G. D. Marijn Veerman, Frank G. A. Jansman, Teun van Gelder, Ron H. J. Mathijssen, Roelof W. F. van Leeuwen

Get full text

Physiologically based pharmacokinetic/pharmacodynamic model for the prediction of morphine brain disposition and analgesia in adults and children. by Laurens F M Verscheijden, Carlijn H C Litjens, Jan B Koenderink, Ron H J Mathijssen, Marcel M Verbeek, Saskia N de Wildt, Frans G M Russel

Get full text

Health-related quality of life and productivity costs in breast cancer patients treated with tamoxifen in the Netherlands by Anne Kleijburg, C. Louwrens Braal, Justin D. Westenberg, Agnes Jager, Stijn L.W. Koolen, Ron H.J. Mathijssen, Carin A. Uyl-de Groot, Pim Wetzelaer, Hannah Penton

Get full text

Suitability of tumor-associated antibodies as predictive biomarker for response to immune checkpoint inhibitors in patients with melanoma: a short report by Ron H J Mathijssen, Reno Debets, Arjen Joosse, Astrid A M van der Veldt, Marco W J Schreurs, Sharon Veenbergen, Karlijn de Joode, Claudia Kransse, Dian Kortleve

Get full text

Tumour growth rate as a tool for response evaluation during PD-1 treatment for non-small cell lung cancer: a retrospective analysis by Deirdre M.H.J. ten Berge, Daniel P. Hurkmans, Ilse den Besten, Jeroen S. Kloover, Ron H.J. Mathijssen, Reno Debets, Egbert F. Smit, Joachim G.J.V. Aerts

Get full text

Design and statistics of pharmacokinetic drug-drug, herb-drug, and food-drug interaction studies in oncology patients by Daan A.C. Lanser, Maud B.A. Van der Kleij, G.D. Marijn Veerman, Neeltje Steeghs, Alwin D.R. Huitema, Ron H.J. Mathijssen, Esther Oomen-de Hoop

Get full text

Correction: Tumor Volume as an Alternative Response Measurement for Imatinib Treated GIST Patients. by Gaia Schiavon, Alessandro Ruggiero, Patrick Schöffski, Bronno van der Holt, Dave J. Bekers, Karel Eechoute, Vincent Vandecaveye, Gabriel P. Krestin, Jaap Verweij, Stefan Sleijfer, Ron H. J. Mathijssen

Get full text

Efficacy and Toxicity of Weekly Carboplatin and Paclitaxel as Induction or Palliative Treatment in Advanced Esophageal Cancer Patients by Femke M. de Man, Ruben A.G. van Eerden, Esther Oomen-de Hoop, Joris N. Veraart, Nadia van Doorn, Leni van Doorn, Ate van der Gaast, Ron H.J. Mathijssen

Get full text

Population Pharmacokinetics of Oxycodone and Metabolites in Patients with Cancer-Related Pain by Bram C. Agema, Astrid W. Oosten, Sebastiaan D.T. Sassen, Wim J.R. Rietdijk, Carin C.D. van der Rijt, Birgit C.P. Koch, Ron H.J. Mathijssen, Stijn L.W. Koolen

Get full text

The Influence of Body Composition on the Systemic Exposure of Paclitaxel in Esophageal Cancer Patients by Leni van Doorn, Marie-Rose B. S. Crombag, Hánah N. Rier, Jeroen L. A. van Vugt, Charlotte van Kesteren, Sander Bins, Ron H. J. Mathijssen, Mark-David Levin, Stijn L. W. Koolen

Get full text

Combining Sorafenib and Immunosuppression in Liver Transplant Recipients with Hepatocellular Carcinoma by Koen G. A. M. Hussaarts, Leni van Doorn, Sander Bins, Dave Sprengers, Peter de Bruijn, Roelof W. F. van Leeuwen, Stijn L. W. Koolen, Teun van Gelder, Ron H. J. Mathijssen

Get full text

A Metabolomics Approach for Predicting OATP1B-Type Transporter-Mediated Drug–Drug Interaction Liabilities by Yang Li, Yan Jin, Hanieh Taheri, Keith T. Schmidt, Alice A. Gibson, Stefan A. J. Buck, Eric D. Eisenmann, Ron H. J. Mathijssen, William D. Figg, Sharyn D. Baker, Alex Sparreboom, Shuiying Hu

Get full text

Toward model-informed precision dosing for tamoxifen: A population-pharmacokinetic model with a continuous CYP2D6 activity scale by Bram C. Agema, Sanne M. Buijs, Sebastiaan D.T. Sassen, Thomas E. Mürdter, Mathias Schwab, Birgit C.P. Koch, Agnes Jager, Ron H.N. van Schaik, Ron H.J. Mathijssen, Stijn L.W. Koolen

Get full text

Capecitabine-induced hand-foot syndrome: A pharmacogenetic study beyond DPYD by Mirjam de With, Leni van Doorn, Demi C. Maasland, Tessa A.M. Mulder, Esther Oomen-de Hoop, Bianca Mostert, Marjolein Y.V. Homs, Samira El Bouazzaoui, Ron H.J. Mathijssen, Ron H.N. van Schaik, Sander Bins

Get full text

Influence of Genetic Variation in <i>COMT</i> on Cisplatin-Induced Nephrotoxicity in Cancer Patients by Bram C. Agema, Stijn L.W. Koolen, Mirjam de With, Nadia van Doorn, Niels Heersche, Esther Oomen-de Hoop, Sabine Visser, Joachim G.J.V. Aerts, Sander Bins, Ron H.N. van Schaik, Ron H.J. Mathijssen

Get full text

Improving the tolerability of osimertinib by identifying its toxic limit by Bram C. Agema, G. D. Marijn Veerman, Christi M. J. Steendam, Daan A. C. Lanser, Tim Preijers, Cor van der Leest, Birgit C. P. Koch, Anne-Marie C. Dingemans, Ron H. J. Mathijssen, Stijn L. W. Koolen

Get full text